Neurocrine Biosciences: Depressive Disorder, Major trials

The registry lists 10 Depressive Disorder, Major studies with Neurocrine Biosciences as lead sponsor. 6 are open to participants now and 2 have results posted.

Phase 2 3Phase 3 5Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT07196501Phase 3
• A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorRecruitingNCT07105111Phase 4
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT06966401Phase 3
• NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT06963021Phase 3
• NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT06911112Phase 3
• Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)RecruitingNCT06786624Phase 3
• Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive DyskinesiaCompletedNCT05859698Phase 4Results posted
• Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDDCompletedNCT05165394Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive DisorderCompletedNCT06267846Phase 2
• Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)CompletedNCT05203341Phase 2